Citation Impact
Citing Papers
β-Arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2
2009 StandoutNobel
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
2006
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
2008
Spontaneous tumor rejection by cbl-b –deficient CD8+ T cells
2007
Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression
2013 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Human ITCH E3 Ubiquitin Ligase Deficiency Causes Syndromic Multisystem Autoimmune Disease
2010
c-Kit—A hematopoietic cell essential receptor tyrosine kinase
2007
Base-excision repair of oxidative DNA damage
2007 StandoutNature
NMR structure and mutagenesis of the FADD (Mort1) death-effector domain
1998 Nature
Systems Biology of Growth Factor‐Induced Receptor Endocytosis
2008
Inflammation and cancer
2002 StandoutNature
Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins
2004
mTOR Signaling in Growth Control and Disease
2012 Standout
The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys
2004 StandoutNature
Necroptosis and its role in inflammation
2015 StandoutNature
The reverse stop-signal model for CTLA4 function
2008
Derailed endocytosis: an emerging feature of cancer
2008
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
2009 Nature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis
2016 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells
2009
Analyzing real-time PCR data by the comparative CT method
2008 Standout
The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor
1999
The biochemistry of apoptosis
2000 StandoutNature
Signaling by Kit protein-tyrosine kinase—The stem cell factor receptor
2005
Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas
2010 StandoutNobel
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
The ubiquitin ligase adaptor Ndfip1 regulates T cell-mediated gastrointestinal inflammation and inflammatory bowel disease susceptibility
2010
Caspase structure, proteolytic substrates, and function during apoptotic cell death
1999
Essential Role of the E3 Ubiquitin Ligase Cbl-b in T Cell Anergy Induction
2004
Immunity by ubiquitylation: a reversible process of modification
2005
Origin and physiological roles of inflammation
2008 StandoutNature
Spinning molecular immunology into successful immunotherapy
2002
Synthetic lethality: the road to novel therapies for breast cancer
2016
Cancer Immunotherapy by Dendritic Cells
2008
Genetics and pathogenesis of inflammatory bowel disease
2011 StandoutNature
Structurally Distinct Phosphatases CD45 and CD148 Both Regulate B Cell and Macrophage Immunoreceptor Signaling
2008
Nedd4 Mediates Agonist-dependent Ubiquitination, Lysosomal Targeting, and Degradation of the β2-Adrenergic Receptor
2008
Points of control in inflammation
2002 StandoutNature
The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs
2011
E3 ubiquitin ligases as T cell anergy factors
2004
Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1
1999 StandoutNobel
Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells
2008
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
GRAIL
2003
Clues from cell metabolism
2010 StandoutNatureNobel
I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development
2010 StandoutNobel
Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation
2006
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo
2012
Inhibition of the Met Receptor in Mesothelioma
2005
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
2009 StandoutNobel
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
2002
Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses
2011 StandoutNobel
Trastuzumab in the management of early and advanced stage breast cancer.
2007
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
2005
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production
2008 StandoutNature
Disruption of Myc-Tubulin Interaction by Hyperphosphorylation of c-Myc during Mitosis or by Constitutive Hyperphosphorylation of Mutant c-Myc in Burkitt's Lymphoma
2000
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Spermidine in health and disease
2018 StandoutScience
Repair and Genetic Consequences of Endogenous DNA Base Damage in Mammalian Cells
2004 StandoutNobel
A Tale of Two Cbls: Interplay of c-Cbl and Cbl-b in Epidermal Growth Factor Receptor Downregulation
2008
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
2000 StandoutScience
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB−/− Mice
2002
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
The Cyclin-dependent Kinase Cdk2 Regulates Thymocyte Apoptosis
1999
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
T Cell Activation
2009 Standout
The Phosphoinositide 3-Kinase Pathway
2002 StandoutScience
Works of Stan Lipkowitz being referenced
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
2001
cbl-3: a new mammalian cbl family protein
1999
WW Domain HECT E3s Target Cbl RING Finger E3s for Proteasomal Degradation
2003
Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b
2004
Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines
2000
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
2000 Nature
Thymidylate synthase as an oncogene
2004
A Conserved DpYR Motif in the Juxtamembrane Domain of the Met Receptor Family Forms an Atypical c-Cbl/Cbl-b Tyrosine Kinase Binding Domain Binding Site Required for Suppression of Oncogenic Activation
2004
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding
1997
cbl-b inhibits epidermal growth factor receptor signaling
1999
Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells
2001
Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex
2001
Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404).
2016
The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.
1996
Cutting Edge: Regulation of T Cell Activation Threshold by CD28 Costimulation Through Targeting Cbl-b for Ubiquitination
2002
Fas expression and function in normal and malignant breast cell lines.
1996
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2004
Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl)
2004